Sustained Response to Erenumab over Time in Patients with Episodic Migraine

被引：0
|
作者：
McAllister, P.
Turner, I. M.
Reuter, U.
Vargas, B. B.
Scanlon, J., V
Klatt, J.
Richards, S.
Chou, D. E.
Lima, G. Paiva Da Silva
机构：
来源：
HEADACHE | 2019年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P137
引用
收藏
页码：111 / 112
页数：2
相关论文
共 50 条
  • [21] One-year sustained efficacy of erenumab in episodic migraine Results of the STRIVE study
    Goadsby, Peter J.
    Reuter, Uwe
    Hallstroem, Yngve
    Broessner, Gregor
    Bonner, Jo H.
    Zhang, Feng
    Wright, Ian K.
    Chou, Denise E.
    Klatt, Jan
    Picard, Hernan
    Lenz, Robert A.
    Mikol, Daniel D.
    NEUROLOGY, 2020, 95 (05) : E469 - E479
  • [22] Sustained Efficacy over 1 Year of Treatment with Erenumab: Results from the Extension Phase of the STRIVE Study in Episodic Migraine
    Goadsby, P. J.
    Hallstrom, Y.
    Broessner, G.
    Bonner, J. H.
    Zhang, F.
    Sapra, S.
    Chou, D. E.
    Klatt, J.
    Pichard, H.
    Lenz, R. A.
    Mikol, D. D.
    HEADACHE, 2018, 58 (08): : 1313 - 1313
  • [23] Sustained benefit of monthly erenumab versus daily oral preventives in episodic migraine patients from APPRAISE study
    Gil-Gouveia, R.
    Dolezil, D.
    Paemeleire, K.
    Stepien, A.
    Stude, P.
    Lopez, C.
    Stites, T.
    Ritter, S.
    Babanrao, Pisal C.
    Snellman, J.
    Ferraris, M.
    Pozo-Rosich, P.
    HEADACHE, 2023, 63 : 169 - 169
  • [24] Sustained benefit of monthly erenumab versus daily oral preventives in episodic migraine patients from APPRAISE study
    Gil-Gouveia, R.
    Dolezil, D.
    Paemeleire, K.
    Stepien, A.
    Stude, P.
    Lopez, C.
    Stites, T.
    Ritter, S.
    Pisal, C.
    Snellman, J.
    Ferraris, M.
    Pozo-Rosich, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 272 - 272
  • [25] Effect of switching migraine preventive SoC treatments on therapeutic response compared to patients treated continuously with erenumab in patients with episodic migraine
    Pozo-Rosich, Patricia
    Dolezil, David
    Paemeleire, Koen
    Stepien, Adam
    Stude, Philipp
    Lopez, Cristina Lopez
    Stites, Tracy
    Ritter, Shannon
    Maca, Jeff
    Ferraris, Matias
    Snellman, Josefin
    Gil-Gouveia, Raquel
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 54 - 55
  • [26] Evaluation of the effect of erenumab on migraine-specific questionnaire in patients with chronic and episodic migraine
    Chen, Po-Wei
    Karlsson, Mats O.
    Ueckert, Sebastian
    Pritchard-Bell, Ari
    Hsu, Cheng-Pang
    Dutta, Sandeep
    Ahamadi, Malidi
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (12): : 1988 - 2000
  • [27] EFFICACY AND SAFETY OF ERENUMAB IN PATIENTS WITH EPISODIC MIGRAINE FROM THE EMPOWER STUDY
    Wang, Shuu-Jiun
    Roxas, Artemio, Jr.
    Saravia, Bibiana
    Kim, Byung-Kun
    Chowdhury, Debashish
    Riachi, Naji
    Tai, Mei-Ling Sharon
    Tanprawate, Surat
    Tran, Tai Ngoc
    Jing, Zhao Yi
    Mikol, Daniel
    Pandhi, Shaloo
    Wen, Shihua
    Mondal, Subhayan
    Tenenbaum, Nadia
    Hours-Zesiger, Peggy
    CEPHALALGIA, 2020, 40 : 67 - 69
  • [28] Treatment response to erenumab in refractory migraine patients
    Messina, R.
    Cetta, I.
    Guerrieri, S.
    Colombo, B.
    Filippi, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 864 - 864
  • [29] Achievement of response over time with fremanezumab in the treatment of chronic and episodic migraine
    Silberstein, Stephen D.
    Lipton, Richard B.
    Diamond, Merle L.
    Cohen, Joshua M.
    Yang, Ronghua
    Jiang, Bo
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [30] Achievement of Response over Time with Fremanezumab in the Treatment of Chronic and Episodic Migraine
    Silberstein, S. D.
    Lipton, R. B.
    Diamond, M. L.
    Cohen, J. M.
    Yang, R.
    Jiang, B.
    HEADACHE, 2018, 58 (08): : 1300 - 1301
12345